Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
Launched by NOVO NORDISK A/S · Oct 20, 2016
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male, age at least 18 years at the time of signing informed consent
- • History of more than 150 exposure days to any factor VIII products
- • Subjects with the diagnosis of congenital haemophilia A with factor VIII activity below 1%, based on medical records
- Exclusion Criteria:
- • Known history of factor VIII inhibitors
- • Inhibitors to factor VIII (above or equal to 0.6 BU (Bethesda units)) at screening measured by the Nijmegen modified Bethesda method
- • Known congenital or acquired coagulation disorders other than haemophilia A
- • Previous participation in pharmacokinetic sessions with turoctocog alfa in another trial
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Valencia, , Spain
Sofia, , Bulgaria
Madrid, , Spain
Peoria, Illinois, United States
Hannover, , Germany
Taipei, , Taiwan
Richmond, Virginia, United States
Wien, , Austria
Changhua, , Taiwan
Málaga, , Spain
Bonn, , Germany
Belgrade, , Serbia
Vigo, , Spain
Memphis, Tennessee, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials